Neuroprotective role of PDE4 and PDE5 inhibitors in 3-nitropropionic acid induced behavioral and biochemical toxicities in rats

European Journal of Pharmacology

Volumn 714, Issue 1-3, 2013, Pages 515-521

  Thakur, Tarun ^a   Sharma, Sorabh ^a   Kumar, Kushal ^a   Deshmukh, Rahul ^a   Sharma, Pyare Lal ^a  

^a ISF COLLEGE OF PHARMACY   (India)

Author keywords

3 Nitropropionic acid; Huntington's disease; Motor disorder; Oxidative stress; PDE inhibitor

Indexed keywords

3 NITROPROPIONIC ACID; 4 (3 BUTOXY 4 METHOXYBENZYL) 2 IMIDAZOLIDINONE; GLUTATHIONE; LACTATE DEHYDROGENASE; MALONALDEHYDE; NITRITE; PHOSPHODIESTERASE IV INHIBITOR; PHOSPHODIESTERASE V INHIBITOR; SILDENAFIL; SUCCINATE DEHYDROGENASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN HOMOGENATE; CELL DAMAGE; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; HUNTINGTON CHOREA; LIMB MOVEMENT; LOCOMOTION; MAZE TEST; MOTOR DYSFUNCTION; MOTOR PERFORMANCE; NEUROPROTECTION; NEUROTOXICITY; NITROSATIVE STRESS; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; TREATMENT DURATION; WEIGHT REDUCTION;

3-NITROPROPIONIC ACID; HUNTINGTON'S DISEASE; MOTOR DISORDER; OXIDATIVE STRESS; PDE INHIBITOR;

4-(3-BUTOXY-4-METHOXYBENZYL)-2-IMIDAZOLIDINONE; ANIMALS; BEHAVIOR, ANIMAL; BODY WEIGHT; BRAIN; GLUTATHIONE; L-LACTATE DEHYDROGENASE; MALONDIALDEHYDE; MAZE LEARNING; MEMORY; NEUROPROTECTIVE AGENTS; NITRO COMPOUNDS; PHOSPHODIESTERASE 4 INHIBITORS; PHOSPHODIESTERASE 5 INHIBITORS; PIPERAZINES; PROPIONATES; PURINES; RATS; RATS, WISTAR; SUCCINATE DEHYDROGENASE; SULFONES;

EID: 84885475459     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2013.06.035     Document Type: Article

References (67)

1. Beal, M.F., Brouillet, E., Jenkins, B.G., Ferrante, R.J., Kowall, N.W., Miller, J.M., Storey, E., Srivastava, R., Rosen, B.R., Hyman, B.T., 1993. Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid. Journal of Neuroscience 13, 4181-4192. (Pubitemid 23299942)
2. Bender, A.T., Beavo, J.A., 2006. Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. Pharmacological Reviews 58, 488-520. (Pubitemid 44394910)
3. Blum, D., Galas, M.C., Gall, D., Cuvelier, L, Schiffmann, S.N., 2002. Striatal and cortical neurochemical changes induced by chronic metabolic compromise in the 3-nitropropionic model of Huntington's disease. Neurobiology of Disease 10, 410-426. (Pubitemid 35217592)
4. Borisy, F.F., Hwang, P.N., Ronnen, G.Y., Snyder, S.H., 1993. High-affinity CAMP phosphodiesterase and adenosine localized in sensory organs. Brain Research 7, 199-207. (Pubitemid 23154791)
5. Borlongan, C.V., Koutouzis, T.K., Freeman, T.B., Cahill, D.W., Sanberg, P.R., 1995. Behavioral pathology induced by repeated systemic injections of 3-nitropropionic acid mimics the motoric symptoms of Huntington's disease. Brain Research 697, 254-257.
6. Borlongan, C.V., Kanning, K., Poulos, S.G., Freeman, T.B., Cahill, D.W., Sanberg, P.R., 1996. Free radical damage and oxidative stress in Huntington's disease. Journal of the Florida Medical Association 83, 335-341.
7. Brouillet, E., Conde, F, Beal, M.F., Hantraye, P., 1999. Replicating Huntington's disease phenotype in experimental animals. Progress in Neurobiology 59, 427-468. (Pubitemid 29392967)
8. Brouillet, E., Jacquard, C, Bizat, N., Blum, D., 2005. 3-Nitropropionic acid: a mitochondrial toxin to uncover physiopathological mechanisms underlying striatal degeneration in Huntington's disease. Journal of Neurochemistry 95, 1521-1540. (Pubitemid 41804051)
9. Brown, D.M., Hutchison, L., Donaldson, K., MacKenzie, S.J., Dick, CA., Stone, V., 2007. The effect of oxidative stress on macrophages and lung epithelial cells: the role of phosphodiesterases 1 and 4. Toxicology Letters 168, 1-6. (Pubitemid 44914176)
10. Chen, CM., Wu, Y.R., Cheng, M.L., Liu, J.L., Lee, Y.M., Lee, PW, Soong, B.W., Chiu, D.T., 2007. Increased oxidative damage and mitochondrial abnormalities in the peripheral blood of Huntington's disease patients. Biochemical and Biophysical Research Communications 359, 335-340. (Pubitemid 46880509)
11. Choi, Y.S., Lee, B., Cho, H.Y, Reyes, I.B., Pu, X.A., Saido, T.C, Hoyt, K.R., Obrietan, K., 2009. CREB is a key regulator of striatal vulnerability in chemical and genetic models of Huntington's disease. Neurobiology of Disease 36, 259-268.
12. Cramer, H., Warter, J.M., Renaud, B., 1984. Analysis of neurotransmitter metabolites and adenosine 3',5'-monophosphate in the CSF of patients with extrapyramidal motor disorders. Advances in Neurology 40, 431-435.
13. Cruz, A.R., Almaguer-Melian, W, Díaz, CM., Lorigados, L., Bergado, J., 2001. Behavioral and biochemical effects of glutathione depletion in the rat brain. Brain Research Bulletin 55, 327-333. (Pubitemid 32727891)
14. Cruz, R., Almaguer Melian, W, Bergado Rosado, JA, 2003. Glutathione in cognitive function and neurodegeneration. Revista de Neurología 36, 877-886. (Pubitemid 36741425)
15. DeMarch, Z., Giampa, C, Patassini, S., Martorana, A., Bernardi, G., Fusco, F.R., 2007. Beneficial effects of rolipram in a quinolinic acid model of striatal excitotoxicity. Neurobiology of Disease 25, 266-273. (Pubitemid 46127843)
16. DeMarch, Z., Giampa, C, Patassini, S., Bernardi, G., Fusco, F.R., 2008. Beneficial effects of rolipram in the R6/2 mouse model of Huntington's disease. Neurobiology of Disease 30, 375-387.
17. Delghandi, M.P., Johannessen, M., Moens, U., 2005. The cAMP signalling pathway activates CREB through PKA, p38 and MSK1 in NIH 3T3 cells. Cellular Signalling 17, 1343-1351. (Pubitemid 41206644)
18. Deshmukh, R., Sharma, V., Mehan, S., Sharma, N., Bedi, K.L, 2009. Amelioration of intracerebroventricular streptozotocin induced cognitive dysfunction and oxidative stress by vinpocetine - a PDE1 inhibitor. European Journal of Pharmacology 620, 49-56.
19. Ding, G., Jiang, Q., Li, L, Zhang, L, Zhang, Z.G., Ledbetter, K.A., Panda, S., Davarani, S.P, Athiraman, H., Li, Q., Ewing, J.R., Chopp, M., 2008. Magnetic resonance imaging investigation of axonal remodeling and angiogenesis after embolic stroke in sildenafil-treated rats. Journal of Cerebral Blood Flow & Metabolism 28, 1440-1448.
20. Dringen, R., 2000. Metabolism and functions of glutathione in brain. Progress in Neurobiology 62, 649-671. (Pubitemid 30407139)
21. Duan, W., Guo, Z., Mattson, M.P., 2000. Participation of par-4 in the degeneration of striatal neurons induced by metabolic compromise with 3-nitropropionic acid. Experimental Neurology 165, 1-11.
22. Ellman, G.L., 1959. Tissue sulfhydryl groups. Archives of Biochemistry and Biophysics 82, 70-77.
23. Farooq, M.U., Naravetla, B., Moore, P.W., Majid, A, Gupta, R., Kassab, M.Y., 2008. Role of sildenafil in neurological disorders. Clinical Neuropharmacology 31, 353-362.
24. Gil, J.M., Rego, A.C., 2008. Mechanisms of neurodegeneration in Huntington's disease. European Journal of Neuroscience 27, 2803-2820. (Pubitemid 351832229)
25. Green, LC., Wagner, D.A., Glogowski, J., Skipper, P.L., Wishnok, J.S., Tannenbaum, S.R., 1982. Analysis of nitrate, nitrite, and [15N] nitrate in biological fluids. Analytical Biochemistry 126, 131-138. (Pubitemid 13203451)
26. Hebb, A.L.O., Robertson, H.A., Denovan-Wright, E.M., 2004. Striatal phosphodiesterase mRNA and protein levels are reduced in Huntington's disease transgenic mice prior to the onset of motor symptoms. Neuroscience 123, 967-981. (Pubitemid 38130106)
27. Jiang, H., Nucifora, F.C., Ross, CA., DeFranco, D.B., 2003. Cell death triggered by polyglutamine-expanded huntingtin in a neuronal cell line is associated with degradation of CREB-binding protein. Human Molecular Genetics 12, 1-12. (Pubitemid 36097710)
28. Keene, CD., Rodrigues, CM., Eich, T., Linehan-Stieers, C, Abt, A., Kren, B.T., Steer, C.J., Low, W.C, 2001. A bile acid protects against motor and cognitive deficits and reduces striatal degeneration in the 3-nitropropionic acid model of Huntington's disease. Experimental Neurology 171, 351-360. (Pubitemid 32955297)
29. Kodsi, M.H., Swerdlow, N.R., 1997. Mitochondrial toxin 3-nitropropionic acid produces startle reflex abnormalities and striatal damage in rats that model some features of Huntington's disease. Neuroscience Letters 231, 103-107. (Pubitemid 27386500)
30. Kumar, P., Kumar, A., 2009. Protective effect of rivastigmine against 3-NP induced HD like symptoms. European Journal of Pharmacology 615, 91-101.
31. Kumar, P., Padi, S.S.V., Naidu, P.S., Kumar, A., 2006. Protective effect of antioxidants on 3-nitropropionic acid induced oxidative stress and cognitive impairment. Annals of Neurosciences 13, 41-47.
32. Kumar, P., Padi, S.S.V., Naidu, P.S., Kumar, A., 2007. Cyclooxygenase inhibition attenuates 3-nitropropionic acid-induced neurotoxicity in rats: possible antioxidant mechanisms. Fundamental & Clinical Pharmacology 21, 297-306. (Pubitemid 46800477)
33. Lee, W.T., Chang, C, 2004. Magnetic resonance imaging and spectroscopy in assessing 3-nitropropionic acid-induced brain lesions: an animal model of Huntington's disease. Progress in Neurobiology 72, 87-110. (Pubitemid 38519588)
34. Li, S.H., Yu, Z.X., Li, CL., Nguyen, H.P., Zhou, YX., Deng, C, Li, X.J., 2003. Lack of huntingtin-associated protein-1 causes neuronal death resembling hypothalamic degeneration in Huntington's disease. Journal of Neuroscience 23, 6956-6964. (Pubitemid 36951224)
35. Livingstone, C, Davis, J., 2007. Targeting therapeutics against glutathione depletion in diabetes and its complications. British Journal of Diabetes & Vascular Disease 7, 258-265.
36. Lowry, O.H., Rosebrough, N.J., Farr, A.L, Randall, R.J., 1951. Protein measurement with the Folin phenol reagent. Journal of Biological Chemistry 193, 265-275.
37. Miller, P.J., Zaborszky, L., 1997. 3-Nitropropionic acid neurotoxicity: visualization by silver staining and implications for use as an animal model of Huntington's disease. Experimental Neurology 146, 212-229. (Pubitemid 27319736)
38. Mostafa, T, 2008. Oral phosphodiesterase type 5 inhibitors: nonerectogenic beneficial uses. Journal of Sexual Medicine 5, 2502-2518.
39. Nucifora, F.C., Sasaki, M., Peters, M.F., Huang, H., Cooper, J.K., Yamada, M., Takahashi, H., Tsuji, S., Troncoso, J., Dawson, V.L., Dawson, T.M., Ross, CA., 2001. Interference by huntingtin and atrophin-1 with cbp-mediated transcription leading to cellular toxicity. Science 291, 2423-2428. (Pubitemid 32231807)
40. Pages, B.M., Zala, D., Humbert, S., Saudou, F., 2006. Huntington's disease: from huntingtin function and dysfunction to therapeutic strategies. Cellular and Molecular Life Sciences 63, 2642-2660. (Pubitemid 44800717)
41. Perk, H., Armagan, A., Naziroglu, M., Soyupek, S., Hoscan, M.B., Sutcu, R., Ozorak, A., Delibas, N., 2008. Sildenafil citrate as a phosphodiesterase inhibitor has an antioxidant effect in the blood of men. Journal of Clinical Pharmacy and Therapeutics 33, 635-640.
42. Petersen, A., Gil, J., Maat-Schieman, M.L., Bjorkqvist, M., Tanila, H., Araujo, I.M., Smith, R., Popovic, N., Wierup, N., Norlen, P., Li, J.Y, Roos, RA, Sundler, F., Mulder, H., Brundin, P., 2005. Orexin loss in Huntington's disease. Human Molecular Genetics 14, 39-47. (Pubitemid 40123461)
43. Prickaerts, J., Sik, A., van Staveren, W. C, Koopmans, G., Steinbusch, H.W., van der Staay, FJ., de Vente, J., Blokland, A., 2004. Phosphodiesterase type 5 inhibition improves early memory consolidation of object information. Neurochemistry International 45, 915-928. (Pubitemid 39108064)
44. Puerta, E., Hervias, I., Barros-Minones, L, Jordan, J., Ricobaraza, A., Cuadrado-Tejedor, M., García-Osta, A., Aguirre, N., 2010. Sildenafil protects against 3-nitropropionic acid neurotoxicity through the modulation of calpain, CREB, and BDNF. Neurobiology of Disease 38, 237-245.
45. Puzzo, D., Staniszewski, A., Deng, S.X., Privitera, L., Leznik, E., Liu, S., Zhang, H., Feng, Y., Palmeri, A., Landry, D.W., Arancio, O., 2009. Phosphodiesterase 5 inhibition improves synaptic function, memory, and amyloid-beta load in an Alzheimer's disease mouse model. Journal of Neuroscience 29, 8075-8086.
46. Reneerkens, O.A., Rutten, K., Steinbusch, H.W., Blokland, A., Prickaerts, J., 2009. Selective phosphodiesterase inhibitors: a promising target for cognition enhancement. Psychopharmacology 202, 419-443.
47. Rezvanfar, M.A., Rnjbar, A., Baeeri, M., Mohammadirad, A., Abdollahi, M., 2010. Biochemical evidence on positive effects of rolipram a phosphodiesterase-4 inhibitor in malathion-induced toxic stress in rat blood and brain mitochondria. Pesticide Biochemistry and Physiology 98, 135-143.
48. Royl, G., Balkaya, M., Lehmann, S., Lehnardt, S., Stohlmann, K., Lindauer, U., Endres, M., Dirnagl, U., Meisel, A., 2009. Effects of the PDE5-inhibitor vardenafil in a mouse stroke model. Brain Research 1265, 148-157.
49. Rusin, L.J., Duell, E.A., Voorhees, J.J., 1978. Papaverine and Ro 20-1724 inhibit cyclic nucleotide phosphodiesterase activity and increase cyclic AMP levels in psoriatic epidermis in vitro. Journal of Investigative Dermatology 71, 154-156. (Pubitemid 9008962)
50. Sharma, V., Bala, A., Deshmukh, R., Bedi, K.L., Sharma, P.L., 2012. Neuroprotective effect of RO-20-1724 - a phosphodiesterase 4 inhibitor against intracerebroven-tricular streptozotocin induced cognitive deficit and oxidative stress in rats. Pharmacology Biochemistry and Behavior 101, 239-245.
51. Shear, D.A., Dong, J., Gundy, C.D., Haik-Creguer, K.L., Dunbar, G.L., 1998. Comparison of intrastriatal injections of quinolinic acid and 3-nitropropionic acid for use in animal models of Huntington's disease. Progress in Neuro-Psychopharmacology & Biological Psychiatry 22, 1217-1240. (Pubitemid 28511596)
52. Shear, D.A., Haik, K.L., Dunbar, G.L., 2000. Creatine reduces 3-nitropropionic-acid-induced cognitive and motor abnormalities in rats. NeuroReport 11, 1833-1837. (Pubitemid 30429120)
53. Silva, A.J., Kogan, J.H., Frankland, P.W., Kida, S., 1998. CREB and memory. Annual Review of Neuroscience 21, 127-148. (Pubitemid 28150661)
54. Steffan, J.S., Kazantsev, A., Spasic-Boskovic, O., Greenwald, M., Zhu, Y.Z., Gohler, H., Wanker, E.E., Bates, G.P., Housman, D.E., Thompson, L.M., 2000. The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription. Proceedings of the National Academy of Sciences of the United States of America 97, 6763-6768. (Pubitemid 30412788)
55. Steffan, J.S., Bodai, L., Pallos, J., Poelman, M., McCampbell, A., Apostol, B.L., Kazantsev, A., Schmidt, E., Zhu, Y.Z., Greenwald, M., Kurokawa, R., Housman, D.E., Jackson, G.R., Marsh, J.L., Thompson, L.M., 2001. Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila. Nature 413, 739-743. (Pubitemid 33009952)
56. Sugars, K.L., Rubinsztein, D.C., 2003. Transcriptional abnormalities in Huntington disease. Trends in Genetics 19, 233-238. (Pubitemid 36511427)
57. Sugars, K.L., Brown, R., Cook, L.J., Swartz, J., Rubinsztein, D.C., 2004. Decreased cAMP response element-mediated transcription: an early event in exon 1 and full-length cell models of Huntington's disease that contributes to polyglutamine pathogenesis. Journal of Biological Chemistry 279, 4988-4999. (Pubitemid 38199095)
58. Sun, Y., 1990. Free radicals, antioxidant enzymes, and carcinogenesis. Free Radical Biology & Medicine 8, 583-599. (Pubitemid 20204421)
59. Tejedor, M.C., Hervias, I., Ricobaraza1, A., Puerta, E., Perez, R.J.M., Barroso, C.G., Franco, R., Aguirre, N., García-Osta, A., 2011. Sildenafil restores cognitive function without affecting b-amyloid burden in a mouse model of Alzheimer's disease. British Journal of Pharmacology 164, 2029-2041.
60. Tunez, I., Montilla, P., Munoz, M.C., Drucker-Colin, R., 2004. Effect of nicotine on 3-nitropropionic acid-induced oxidative stress in synaptosomes. European Journal of Pharmacology 504, 169-175. (Pubitemid 39488212)
61. Uthayathas, S., Karuppagounder, S.S., Thrash, B.M., Parameshwaran, K., Suppiramaniam, V., Dhanasekaran, M., 2007. Versatile effects of sildenafil: recent pharmacological applications. Pharmacological Reports 59, 150-163. (Pubitemid 46952406)
62. Vis, J.C., Verbeek, M.M., De Waal, R.M., Ten Donkelaar, H.J., Kremer, H.P., 1999. 3-Nitropropionic acid induces a spectrum of Huntington's disease-like neuro-pathology in rat striatum. Neuropathology and Applied Neurobiology 25, 513-521. (Pubitemid 30045425)
63. Walker, F.O., 2007. Huntington's disease. Lancet 369, 218-228. (Pubitemid 46107685)
64. Wills, E.D., 1966. Mechanisms of lipid peroxide formation in animal tissues. Biochemical Journal 99, 667-676.
65. Zhang, R., Wang, Y., Zhang, Li, Zhang, Z., Tsang, W., Lu, M., Zhang, L., Chopp, M., 2002. Sildenafil (Viagra) induces neurogenesis and promotes functional recovery after stroke in rats. Stroke 33, 2675-2680. (Pubitemid 35266440)
66. Zuccato, C., Ciammola, A., Rigamonti, D., Leavitt, B.R., Goffredo, D., Conti, L., MacDonald, M.E., Friedlander, R.M., Silani, V., Hayden, M.R., Timmusk, T., Sipione, S., Cattaneo, E., 2001. Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease. Science 293, 493-498. (Pubitemid 32679077)
67. Zuccato, C., Valenza, M., Cattaneo, E., 2010. Molecular mechanisms and potential therapeutical targets in Huntington's disease. Physiological Reviews 90, 905-981.